Soligenix, a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs. The publication highlights the therapy's safety profile, non-mutagenic mechanism, and demonstrated efficacy across studies, while supporting its potential as a first-line treatment option.
The company is advancing its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. This development represents a significant step forward for patients suffering from cutaneous T-cell lymphoma, a rare cancer affecting the skin that has limited treatment options.
HyBryte represents a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. The therapy's non-mutagenic mechanism is particularly important for cancer treatments, as it reduces the risk of secondary malignancies that can occur with other therapies. The published data in Expert Opinion on Investigational Drugs provides independent validation of the treatment approach and could influence clinical practice guidelines once regulatory approvals are obtained.
Beyond cutaneous T-cell lymphoma, Soligenix is expanding synthetic hypericin development into psoriasis through its SGX302 program. The company's broader pipeline includes first-in-class innate defense regulator technology with dusquetide for inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease. These developments in the Specialized BioTherapeutics business segment address significant unmet medical needs in rare disease populations.
The company's Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax for COVID-19 prevention. These programs incorporate the company's proprietary heat stabilization platform technology known as ThermoVax and have been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The publication of HyBryte clinical data in a peer-reviewed journal represents a critical milestone in the drug development process, providing the scientific community with detailed information about the therapy's mechanism, safety, and efficacy. For patients with cutaneous T-cell lymphoma, this development offers hope for a new treatment option that could potentially become a first-line therapy. The interim analysis expected in 2026 for the FLASH2 Phase 3 trial will provide additional data to support regulatory submissions and potential commercialization.
Investors and stakeholders can find additional information about Soligenix's developments through the company's newsroom at https://ibn.fm/SNGX. The full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer. The publication of this clinical data marks an important step in validating HyBryte's potential to address the significant unmet medical need in cutaneous T-cell lymphoma treatment.
